Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP12 | P39900 | 1/20 | 0.41 |
| ▸ | RAF1 | P04049 | 1/20 | 0.38 |
| ▸ | BRAF | P15056 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 3/20 | 0.38 |
| ▸ | ACLY | P53396 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14804032 | 0.87 | KCNH2 (0.35) | MMP12RAF1BRAFALDH1A1MAPT | |
| SCHEMBL9920485 | 0.81 | MMP12 (0.64) | MMP12RAF1BRAFPARP1ACLY | |
| SCHEMBL12689382 | 0.78 | MMP12 (0.65) | MMP12PARP1ALDH1A1MAPTKDM4E | |
| SCHEMBL17660596 | 0.75 | LMNA (0.33) | ALDH1A1MAPTLMNAHTTKMT2A | |
| SCHEMBL12928758 | 0.74 | MMP12 (0.41) | MMP12PARP1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL69977 | 0.73 | MAPT (0.40) | MMP12ALDH1A1MAPTLMNAHTT | |
| SCHEMBL9924217 | 0.71 | HPGD (0.40) | ALDH1A1MAPTLMNAHTTKMT2A | |
| SCHEMBL10095220 | 0.71 | ALOX5 (0.48) | MMP12PARP1KMT2ANPSR1 | |
| SCHEMBL14072147 | 0.71 | PARP1 (0.48) | MMP12PARP1ALDH1A1MAPT | |
| SCHEMBL9918340 | 0.71 | KDM4E (0.34) | ALDH1A1KDM4ELMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159446-A1 | Methods and Compositions for Targeting Tregs using CCR8 Inhibitors | NANJING IMMUNOPHAGE BIOMEDICAL CO., LTD. (CN) | 2023-05-25 | — | — | US | disclosed |
| US-9266892-B2 | Fused pyrazoles as FGFR inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2016-02-23 | — | — | US | disclosed |
| US-20140171405-A1 | Fused Pyrazoles as FGFR Inhibitors | INCYTE CORPORATION (US) | 2014-06-19 | — | — | US | disclosed |
| US-20130071415-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2013-03-21 | — | — | US | disclosed |
| US-20120149691-A1 | Pyrrolo [1,2-b] Pyridazine Derivatives as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20090005375-A1 | ACETYL COENZYME A CARBOXYLASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149691-A1 | Pyrrolo [1,2-b] Pyridazine Derivatives as Janus Kinase Inhibitors | JAK1, JAK2, JAK3 | MMP12 1666/4885RAF1 235/4885BRAF 156/4885 |
| US-20140171405-A1 | Fused Pyrazoles as FGFR Inhibitors | FGFR1, FGFR3, FGFR2 | MMP12 3126/4885RAF1 65/4885BRAF 121/4885 |
| US-20230159446-A1 | Methods and Compositions for Targeting Tregs using CCR8 Inhibitors | CCR8, CCR1, CCR3 | MMP12 926/4885RAF1 688/4885BRAF 566/4885 |
| US-20130071415-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | JAK2, JAK1, JAK3 | MMP12 1550/4885RAF1 62/4885BRAF 50/4885 |
| US-20090005375-A1 | ACETYL COENZYME A CARBOXYLASE INHIBITORS | ACACA, ACACB, ACAT1 | MMP12 3455/4885RAF1 2392/4885BRAF 3595/4885 |
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | JAK2, JAK1, JAK3 | MMP12 1674/4885RAF1 63/4885BRAF 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.